Joel Schlessinger M.D.

Thanks in part to a study performed by Dr. Joel Schlessinger, a new rosacea drug has been approved by the United States Food and Drug Administration.

Alpha-2 adrenergic agonist brimonidine, also known as Mirvaso, was recently approved by the FDA to treat facial redness in rosacea patients. This is the first topical gel treatment specifically indicated for the persistent facial erythema of rosacea.

Rosacea is a common skin disorder that affects over 16 million Americans. It is commonly characterized by redness on the cheeks, nose, chin or forehead. Over time, untreated rosacea can result in bumps and pimples that may grow swollen. Rosacea is more likely to affect those with fair skin who tend to blush easily.

Mirvaso works by constricting dilated facial blood vessels that cause redness and inflammation. This helps soothe irritation and keep redness under control.

Dr. Joel Schlessinger and associates at the Advanced Skin Research Center conducted studies on this drug to help it receive FDA approval.

In two separate month-long studies, 550 patients who used Mirvaso once a day to the forehead, chin, nose and cheeks saw significant improvement in facial redness compared to those who used a placebo.

Dr. Schlessinger is very happy to see that this drug has been approved by the FDA. The Advanced Skin Research Center in Omaha, Neb. has conducted over 150 research studies, investigating medications and treatments as well as cosmetic procedures.

Learn more about other studies conducted by Dr. Joel Schlessinger here.